Co-Diagnostics (Nasdaq: CODX) launches clinical trial for multiplex respiratory test as FDA approval push begins

Co-Diagnostics, Inc. (Nasdaq: CODX), a U.S.-based molecular diagnostics developer, has officially launched clinical performance evaluations for its new Co-Dx PCR Flu A/B, COVID-19, RSV Test Kit. The company said the clinical trial is designed to generate evidence for a 510(k) submission to the United States Food and Drug Administration (FDA) to support regulatory clearance of both the multiplex test and its compact Co-Dx PCR Pro instrument. The move marks a critical step in Co-Diagnostics’ strategy to commercialize a decentralized, near-patient testing platform tailored for respiratory infections.

The announcement comes at a time when healthcare providers are facing sustained demand for accurate, rapid diagnostic tools for respiratory illnesses such as influenza, COVID-19, and respiratory syncytial virus (RSV). Co-Diagnostics has engineered its platform to meet the needs of decentralized care settings such as physicians’ offices, urgent care centers, and clinics, offering lab-grade accuracy without requiring traditional laboratory infrastructure. The use of reverse-transcriptase polymerase chain reaction (RT-PCR) as the testing method underscores the company’s aim to retain high diagnostic sensitivity and specificity in portable settings.

Co-Diagnostics chief executive officer Dwight Egan said the test’s progression into clinical trials reflects the company’s commitment to regulatory pathways and long-term commercial readiness. He noted that the team has worked extensively to advance the platform to a stage where it is ready for validation in real-world clinical settings. Egan added that the platform is designed to fulfill growing market needs for decentralized molecular diagnostics, particularly during seasonal surges of respiratory infections when centralized labs can become bottlenecked.

How Co-Diagnostics is positioning its PCR Pro system for decentralized respiratory testing

While the United States Food and Drug Administration remains the primary regulatory focus, Egan confirmed that the company also anticipates filing with other agencies, including the Saudi Food and Drug Authority. This reflects Co-Diagnostics’ wider global strategy to gain early traction in geographies with expanding healthcare infrastructure investment, especially in the wake of public health modernization initiatives such as Saudi Arabia’s Vision 2030.

The Co-Dx PCR Flu A/B, COVID-19, RSV Test Kit is configured for simultaneous detection and differentiation of the four viral pathogens in a single run. This multiplexing capability is expected to provide both clinical efficiency and economic value in high-throughput or fast-turnaround environments. The Co-Dx PCR Pro instrument, designed as a portable RT-PCR system, aims to deliver lab-quality results at the point of care without the complexity or cost of central lab testing.

Although the platform is not yet commercially available, the company confirmed that the Co-Dx PCR product line, which also includes Co-Dx PCR Home and associated software tools, is intended to serve both professional and at-home diagnostic markets. All components of the platform are currently under regulatory review and will be subject to FDA or international authority approval prior to sale.

How big is the global opportunity for multiplex PCR testing in respiratory diagnostics?

The global market for respiratory infectious disease diagnostics is expected to continue expanding over the next five years. According to a recent Grand View Research report referenced by Co-Diagnostics, the global market was valued at approximately USD 54.58 billion in 2024. Molecular diagnostics currently account for around two-thirds of that total value. North America remains the largest market for such tests, though emerging markets in the Middle East and Asia are gaining momentum.

By 2030, global market value is projected to rise to USD 73.56 billion, driven in large part by increasing demand for point-of-care diagnostics. Physician offices and urgent care facilities are seeing greater volumes of patients seeking rapid answers for respiratory illnesses, and public awareness around early detection has improved since the onset of the COVID-19 pandemic. Multiplexed assays that allow clinicians to differentiate among respiratory pathogens in real-time are increasingly seen as essential to optimizing treatment plans and preventing unnecessary use of antivirals or antibiotics.

Why Saudi Arabia and India are emerging as key markets for Co-Diagnostics in 2025 and beyond

In the Middle East, the Kingdom of Saudi Arabia has emerged as a key market for diagnostics firms due to robust investments in healthcare infrastructure and the growing prioritization of disease prevention under Saudi Vision 2030. Co-Diagnostics’ intention to submit its trial results to the Saudi Food and Drug Authority places it in alignment with broader public health initiatives in the region. The country has also increased its adoption of digital health tools and decentralized diagnostics, offering an advantageous setting for point-of-care technologies that can scale rapidly.

Co-Diagnostics is also expanding its footprint in the Indian diagnostics market via its joint venture, CoSara Diagnostics. In addition to the upper respiratory multiplex test, CoSara is preparing to conduct clinical evaluations for other assays on the Co-Dx PCR platform, including tests for tuberculosis and human papillomavirus (HPV). India’s diagnostics market remains price-sensitive but increasingly receptive to point-of-care solutions that can serve rural and semi-urban areas with limited lab access.

How Co-Dx PCR is designed to bring RT-PCR quality to near-patient and at-home environments

By focusing on diseases with both high public health impact and unmet testing needs, Co-Diagnostics is positioning its platform as a flexible solution across both infectious disease and broader molecular testing applications. The platform’s mobile integration and data connectivity features are also being developed to support remote result delivery, electronic health record (EHR) integration, and public health reporting.

As clinical testing progresses, analysts tracking the diagnostics space are watching closely for trial outcomes and timeline visibility. While the firm has not provided specific launch timelines, it has indicated that results from the current evaluations could inform a formal submission to the United States Food and Drug Administration within the next few quarters. The outcome of the FDA review process, along with feedback from other regulators such as the Saudi Food and Drug Authority, will be pivotal in shaping the commercial trajectory of the Co-Dx PCR product family.

What are investors watching as Co-Diagnostics pivots toward platform-based growth in diagnostics?

Co-Diagnostics has not disclosed expected pricing or revenue contribution from the multiplex test. However, sentiment among institutional investors appears cautiously optimistic, particularly in light of the company’s post-COVID pivot toward platform-based diagnostics. Analysts believe that successful approval of the respiratory panel would validate the utility of the Co-Dx PCR Pro instrument and pave the way for additional assays in the pipeline. The company’s focus on decentralization is seen as timely, as healthcare delivery models shift away from hospital-centric testing toward distributed, on-demand diagnostics.

Shares of Co-Diagnostics have exhibited volatility throughout 2025, influenced by shifting investor expectations following pandemic-era highs. While the company no longer benefits from emergency use authorizations tied to COVID-19, its longer-term roadmap in platform diagnostics has attracted renewed attention from sector specialists. The successful transition from a single-product firm to a scalable platform player remains a key narrative that investors are watching.

What comes next in Co-Diagnostics’ commercialization strategy and global expansion roadmap

Looking ahead, institutional interest is likely to concentrate on three fronts. First, the performance data from clinical evaluations will determine the company’s regulatory momentum. Second, Co-Diagnostics’ ability to scale manufacturing and distribution infrastructure in tandem with regulatory approvals will impact time-to-market. And third, the level of adoption in international markets like India and Saudi Arabia could become early indicators of broader commercial traction.

With point-of-care testing gaining strategic priority in healthcare systems around the world, Co-Diagnostics’ clinical trial represents a foundational step in entering a market that is both large in scale and increasingly competitive. The next six to nine months are expected to be pivotal in validating whether the company’s technology, positioning, and regulatory strategy can converge to unlock sustainable revenue from decentralized diagnostics.

Key takeaways: What the Co-Diagnostics clinical trial means for its FDA roadmap and global strategy

• Co-Diagnostics, Inc. (Nasdaq: CODX) has begun clinical evaluations for its multiplex Co-Dx PCR Flu A/B, COVID-19, RSV Test Kit on the portable Co-Dx PCR Pro™ platform.

• The trial is designed to support a 510(k) submission to the United States Food and Drug Administration and potentially other regulators, including the Saudi Food and Drug Authority.

• The test simultaneously detects four respiratory pathogens using RT-PCR and is tailored for decentralized, near-patient environments such as clinics and physician offices.

• The global market for respiratory infectious disease diagnostics is projected to grow from USD 54.58 billion in 2024 to USD 73.56 billion by 2030, with molecular diagnostics holding a dominant share.

• Co-Diagnostics plans to expand into India through its joint venture, CoSara Diagnostics, with tuberculosis and HPV tests also approaching the clinical evaluation stage.

• Analysts and investors are watching closely for trial results, FDA filing progress, and commercial rollout plans across U.S., Middle East, and Indian markets.

• The company’s shift from COVID-19 test sales to platform-based diagnostics is seen as a key evolution in its long-term business strategy.

• Institutional sentiment remains cautiously optimistic, with attention on how Co-Diagnostics executes regulatory, manufacturing, and geographic scale-up.

• The trial marks a pivotal moment in validating whether the Co-Dx PCR platform can become a credible point-of-care solution in an increasingly competitive diagnostics landscape.

• Shares of Co-Diagnostics remain volatile, and investor focus will likely intensify as the company approaches regulatory milestones over the next two to three quarters.